{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:58:42Z","timestamp":1787630322273,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019921","name":"National Scleroderma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Formation Biologics and Novartis"},{"name":"Eicos Sciences and Formation Biologics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the efficacy, safety and pharmacodynamics of belumosudil in patients with diffuse cutaneous systemic sclerosis (dcSSc) treated with background immunosuppressive therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible patients were randomised 1:1:1 to receive belumosudil 200\u2009mg once daily (QD) or twice daily (BID), or placebo for 28\u2009weeks (double-blind period). After unblinding, the patients who received belumosudil continued the same dose, whereas the patients who received placebo were re-randomised for one of the belumosudil doses for 24\u2009weeks (open-label extension).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-five and 31 patients were treated in the double-blind and open-label periods, respectively. The study was terminated prematurely, and target enrolment was not met. The primary end point, of CRISS score \u22650.60 at week 24, did not exhibit an efficacy signal in the belumosudil vs placebo groups [odds ratio: 1.06 (0.19\u20135.82; P\u2009=\u20090.9472) for the QD, and 0.39 (0.07\u20132.35; P\u2009=\u20090.3078) for the BID group]. Belumosudil was well tolerated and exhibited similar safety profiles in both double-blind and open-label periods. Tissue-based RNA sequencing analysis revealed FOXP3 upregulation and STAT3, IL23A and TGF-\u03b2 downregulation in patients with CRISS score \u22650.60, which supported the mechanism of action of belumosudil. In blood and tissue samples, trends of decreased fibrosis biomarker levels were seen in the belumosudil-treated group vs placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Efficacy signal for belumosudil could not be detected. Signalling pathway modulation analysis supported the mechanism of action of belumosudil. A trend for decreased fibrosis-related biomarkers was observed in the belumosudil-treated group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT03919799.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf062","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T23:52:41Z","timestamp":1742082761000},"page":"4299-4308","source":"Crossref","is-referenced-by-count":6,"title":["Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0072-6939","authenticated-orcid":false,"given":"Lorinda","family":"Chung","sequence":"first","affiliation":[{"name":"Department of Medicine and Dermatology, Stanford University School of Medicine , Stanford, CA,","place":["USA"]},{"name":"Palo Alto VA Health Care System , Palo Alto, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M","family":"Silver","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina (MUSC) , Charleston, SC,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Steen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Georgetown University , Washington, DC,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-2373","authenticated-orcid":false,"given":"Daniel E","family":"Furst","sequence":"additional","affiliation":[{"name":"Southern California Scleroderma and Rheumatology Centre , Los Angeles, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia V","family":"Castelino","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Massachusetts General Hospital (MGH) , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Trojanowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston University , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Spiera","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hospital of Special Surgery , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2765-0922","authenticated-orcid":false,"given":"Robyn","family":"Domsic","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, University of Pittsburgh School of Medicine , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Rodriguez-Pla","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Mayo Clinic , Scottsdale, AZ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7978-0315","authenticated-orcid":false,"given":"Tamiko R","family":"Katsumoto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Dermatology, Stanford University School of Medicine , Stanford, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Goulaouic","sequence":"additional","affiliation":[{"name":"Sanofi , Chilly-Mazarin,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi , Cambridge, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Espinasse","sequence":"additional","affiliation":[{"name":"Sanofi , Chilly-Mazarin,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souheil","family":"El-Chemaly","sequence":"additional","affiliation":[{"name":"Sanofi , Cambridge, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1622-2802","authenticated-orcid":false,"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi , Cambridge, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"2025070205014442000_keaf062-B1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheum"},{"key":"2025070205014442000_keaf062-B2","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2025070205014442000_keaf062-B3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13075-019-1872-4","article-title":"Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis","volume":"21","author":"Denton","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025070205014442000_keaf062-B4","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/kez532","article-title":"The clinical and economic burden of systemic sclerosis related interstitial lung disease","volume":"59","author":"Morrisroe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025070205014442000_keaf062-B5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3899\/jrheum.180445","article-title":"Economic burden among commercially insured patients with systemic sclerosis in the United States","volume":"46","author":"Zhou","year":"2019","journal-title":"J Rheumatol"},{"key":"2025070205014442000_keaf062-B6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2025070205014442000_keaf062-B7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clim.2011.01.013","article-title":"Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis","volume":"139","author":"Fenoglio","year":"2011","journal-title":"Clin Immunol"},{"key":"2025070205014442000_keaf062-B8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.imlet.2017.09.007","article-title":"Is there a role for IL-17 in the pathogenesis of systemic sclerosis?","volume":"195","author":"Chizzolini","year":"2018","journal-title":"Immunol Lett"},{"key":"2025070205014442000_keaf062-B9","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3389\/fimmu.2018.02356","article-title":"Regulatory T cells in systemic sclerosis","volume":"9","author":"Frantz","year":"2018","journal-title":"Front Immunol"},{"key":"2025070205014442000_keaf062-B10","first-page":"S3","article-title":"Systemic sclerosis: from pathogenesis to targeted therapy","volume":"33","author":"Denton","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025070205014442000_keaf062-B11","first-page":"166","article-title":"Treatment of early diffuse systemic sclerosis skin disease","volume":"31","author":"Frech","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2025070205014442000_keaf062-B12","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2025070205014442000_keaf062-B13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025070205014442000_keaf062-B14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"2025070205014442000_keaf062-B15","first-page":"103343","article-title":"Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease","volume":"70","author":"Ali","year":"2022","journal-title":"Curr Res Transl Med"},{"key":"2025070205014442000_keaf062-B16","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1073\/pnas.1414189111","article-title":"Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism","volume":"111","author":"Zanin-Zhorov","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025070205014442000_keaf062-B17","doi-asserted-by":"crossref","first-page":"108823","DOI":"10.1016\/j.clim.2021.108823","article-title":"ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease","volume":"230","author":"Zanin-Zhorov","year":"2021","journal-title":"Clin Immunol"},{"key":"2025070205014442000_keaf062-B18","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","article-title":"Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a STAT3-dependent mechanism","volume":"127","author":"Flynn","year":"2016","journal-title":"Blood"},{"key":"2025070205014442000_keaf062-B19","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study [published correction appeared in Blood 2022; 139(11): 1772]","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"2025070205014442000_keaf062-B20","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025070205014442000_keaf062-B21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025070205014442000_keaf062-B22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology Provisional Composite Response Index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025070205014442000_keaf062-B23","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.42510","article-title":"Efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous systemic sclerosis","volume":"75","author":"Spiera","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025070205014442000_keaf062-B24","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025070205014442000_keaf062-B25","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025070205014442000_keaf062-B26","doi-asserted-by":"crossref","first-page":"e6203","DOI":"10.1371\/journal.pone.0006203","article-title":"Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis","volume":"4","author":"Fleming","year":"2009","journal-title":"PLoS One"},{"key":"2025070205014442000_keaf062-B27","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/bmt.2013.106","article-title":"Nailfold capillary abnormalities in sclerodermatous chronic GVHD","volume":"48","author":"Hofstee","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2025070205014442000_keaf062-B28","doi-asserted-by":"crossref","first-page":"805708","DOI":"10.3389\/fphar.2022.805708","article-title":"Circulating collagen metabolites and the enhanced liver fibrosis (ELF) score as fibrosis markers in systemic sclerosis","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf062\/62418672\/keaf062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4299\/62418672\/keaf062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4299\/62418672\/keaf062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:01:53Z","timestamp":1751446913000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/7\/4299\/8079064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,3,14]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf062","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,14]]}}}